Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy;El papel de las combinaciones de antirretrovirales a dosis fijas en el tratamiento de la infeccin por VIH-1

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 9, 2010, Pages 615-620

  Llibre, Josep M ^a   Antela, Antonio ^b   Arribas, José Ramón ^c   Domingo, Pere ^d   Gatell, Josep M ^e   López Aldeguer, José ^f   Lozano, Fernando ^g   Miralles, Celia ^h   Moltó, José ^a   Moreno, Santiago ⁱ   Ortega, Enrique ^j   Riera, Melcior ^k   Rivero, Antonio ^l   Villalonga, Concepción ^k   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Hospital Sant Pau   (Spain)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^h HOSPITAL XERAL CALDE   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^k HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^l Hospital Reina Sofa   (Spain)

more..

Author keywords

AIDS; Antiretroviral treatment; Combined treatment; Fixed dose combinations; Human immunodeficiency virus infection; Recommendation

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR;

ANTIVIRAL RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MONOTHERAPY; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; THERAPEUTIC ERROR; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS;

EID: 78049239047     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2010.08.004     Document Type: Review

References (60)

1. P.C. Tien, A.I. Choi, A.R. Zolopa, C. Benson, R. Tracy, and R. Scherzer Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort J Acquir Immune Defic Syndr 2010
2. L.H. Kuller, R. Tracy, W. Belloso, W.S. De, F. Drummond, and H.C. Lane Inflammatory and coagulation biomarkers and mortality in patients with HIV infection PLoS Med 5 2008 e203
3. Panel de expertos de GESIDA y Plan nacional del SIDA. Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. [actualizado 1/2010]. Disponible en: http://www.gesida.seimc.org.
4. F.J. Palella Jr, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, and G.A. Satten Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 1998 853 860
5. F.J. Palella Jr, R.K. Baker, A.C. Moorman, J.S. Chmiel, K.C. Wood, and J.T. Brooks Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study J Acquir Immune Defic Syndr 43 2006 27 34
6. N. Lohse, A.B. Hansen, G. Pedersen, G. Kronborg, J. Gerstoft, and H.T. Sorensen Survival of persons with and without HIV infection in Denmark, 19952005 Ann Intern Med 146 2007 87 95
7. J.M. Llibre, V. Falco, C. Tural, E. Negredo, J.A. Pineda, and J. Munoz The changing face of HIV/AIDS in treated patients Curr HIV Res 7 2009 365 377
8. D.P. Wilson, M.G. Law, A.E. Grulich, D.A. Cooper, and J.M. Kaldor Relation between HIV viral load and infectiousness: a model-based analysis Lancet 372 2008 314 320
9. R.S. Sperling, D.E. Shapiro, R.W. Coombs, J.A. Todd, S.A. Herman, and G.D. McSherry Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group N Engl J Med 335 1996 1621 1629
10. J.A. Bartlett, J.J. Buda, S.B. von, J.A. Mauskopf, E.A. Davis, and R. Elston Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview J Acquir Immune Defic Syndr 41 2006 323 331
11. C.L. Townsend, M. Cortina-Borja, C.S. Peckham, R.A. de, H. Lyall, and P.A. Tookey Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 20002006 AIDS 22 2008 973 981
12. G. Russo, M. Lichtner, F. Traditi, and V. Vullo Is the time for an AIDS-free new generation different in resource-limited and industrialized countries? AIDS 23 2009 293 296
13. S. Attia, M. Egger, M. Muller, M. Zwahlen, and N. Low Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis AIDS 23 2009 1397 1404
14. M.A. Bender, N. Kumarasamy, K.H. Mayer, B. Wang, R.P. Walensky, and T. Flanigan Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India Clin Infect Dis 50 2010 416 425
15. K.A. Freedberg, N. Kumarasamy, E. Losina, A.J. Cecelia, C.A. Scott, and N. Divi Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy AIDS 21 Suppl 4 2007 S117 S128
16. J.B. Nachega, R. Leisegang, D. Bishai, H. Nguyen, M. Hislop, and S. Cleary Association of antiretroviral therapy adherence and health care costs Ann Intern Med 152 2010 18 25
17. K.N. Simpson Economic modeling of HIV treatments Curr Opin HIV AIDS 5 2010 242 248
18. E.J. Beck, G. Harling, S. Gerbase, and P. DeLay The cost of treatment and care for people living with HIV infection: implications of published studies, 19992008 Curr Opin HIV AIDS 5 2010 215 224
19. K.A. Freedberg, E. Losina, M.C. Weinstein, A.D. Paltiel, C.J. Cohen, and G.R. Seage The cost effectiveness of combination antiretroviral therapy for HIV disease N Engl J Med 344 2001 824 831 (Pubitemid 32222162)
20. M.M. Kitahata, S.J. Gange, A.G. Abraham, B. Merriman, M.S. Saag, and A.C. Justice Effect of early versus deferred antiretroviral therapy for HIV on survival N Engl J Med 360 2009 1815 1826
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1,2009;1-161. [consultado 27/6/2010]. Disponible en: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
22. EACS Guidelines. Clinical Management and treatment of HIV Infected Adults in Europe. Version 5. November, 2009. [consultado 27/6/2010]. Disponible en: http://europeanaidsclinicalsociety.org/
23. S.M. Hammer, J.J. Eron Jr, P. Reiss, R.T. Schooley, M.A. Thompson, and S. Walmsley Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel JAMA 300 2008 555 570
24. D. Trono, C. Van Lint, C. Rouzioux, E. Verdin, F. Barre-Sinoussi, and T.W. Chun HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals Science 329 2010 174 180
25. W.M. El-Sadr, J.D. Lundgren, J.D. Neaton, F. Gordin, D. Abrams, and R.C. Arduino CD4 count-guided interruption of antiretroviral treatment N Engl J Med 355 2006 2283 2296
26. A.N. Phillips, A. Carr, J. Neuhaus, F. Visnegarwala, R. Prineas, and W.J. Burman Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial Antivir Ther 13 2008 177 187
27. J. Neuhaus, D.R. Jacobs Jr, J.V. Baker, A. Calmy, D. Duprez, and R.A. La Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection J Infect Dis 201 2010 1788 1795
28. B. Hirschel, and T. Flanigan Is it smart to continue to study treatment interruptions? AIDS 23 2009 757 759
29. L. Ruiz, R. Paredes, G. Gmez, J. Romeu, P. Domingo, and N. Perez-Alvarez Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients AIDS 21 2007 169 178
30. J.M. Llibre, J.M. Schapiro, and B. Clotet Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure Clin Infect Dis 50 2010 872 881
31. J.J. Parienti, K. Ragland, F. Lucht, B.A. de la, S. Dargere, and Y. Yazdanpanah Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication Clin Infect Dis 50 2010 1192 1197
32. V.S. Gill, V.D. Lima, W. Zhang, B. Wynhoven, B. Yip, and R.S. Hogg Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection Clin Infect Dis 50 2010 98 105
33. W.P. Bannister, A. Cozzi-Lepri, B. Clotet, A. Mocroft, J. Kjaer, and P. Reiss Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study J Acquir Immune Defic Syndr 48 2008 324 333
34. A. Cozzi-Lepri, A.N. Phillips, B. Clotet, A. Mocroft, L. Ruiz, and O. Kirk Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study AIDS 22 2008 2187 2198
35. A.M. Wensing, V. van d, G. Angarano, B. Asjo, C. Balotta, and E. Boeri Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management J Infect Dis 192 2005 958 966
36. J.B. Nachega, M. Hislop, D.W. Dowdy, R.E. Chaisson, L. Regensberg, and G. Maartens Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes Ann Intern Med 146 2007 564 573
37. A.H. Gradman, J.N. Basile, B.L. Carter, G.L. Bakris, B.J. Materson, and H.R. Black Combination therapy in hypertension J Am Soc Hypertens 4 2010 90 98
38. T. Moulding, A.K. Dutt, and L.B. Reichman Fixed-dose combinations of antituberculous medications to prevent drug resistance Ann Intern Med 122 1995 951 954
39. P.Y. Norval, B. Blomberg, M.E. Kitler, C. Dye, and S. Spinaci Estimate of the global market for rifampicin-containing fixed-dose combination tablets Int J Tuberc Lung Dis 3 11 Suppl 3 1999 S292 S300
40. Aguado JM, Rufi G, Garca Rodrguez J, Solera J, Moreno S. Tuberculosis. Protocolos Clnicos de la Sociedad Espaola de Infecciones y Microbiologia Clnica (SEIMC). Protocolo VII. [consultado 28/6/2010]. Disponible en: www.seimc.org
41. B. Blomberg, S. Spinaci, B. Fourie, and R. Laing The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis Bull World Health Organ 79 2001 61 68
42. S. Bangalore, G. Kamalakkannan, S. Parkar, and F.H. Messerli Fixed-dose combinations improve medication compliance: a meta-analysis Am J Med 120 2007 713 719
43. J. Connor, N. Rafter, and A. Rodgers Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review Bull World Health Organ 82 2004 935 939
44. J.J. Parienti, D.R. Bangsberg, R. Verdon, and E.M. Gardner Better adherence with once-daily antiretroviral regimens: a meta-analysis Clin Infect Dis 48 2009 484 488
45. C. Laurent, C. Kouanfack, S. Koulla-Shiro, N. Nkoue, A. Bourgeois, and A. Calmy Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial Lancet 364 2004 29 34
46. M. Airoldi, M. Zaccarelli, L. Bisi, T. Bini, A. Antinori, and C. Mussini One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects Patient Prefer Adherence 4 2010 115 125
47. S.L. Hodder, K. Mounzer, E. Dejesus, R. Ebrahimi, K. Grimm, and S. Esker Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF AIDS Patient Care STDS 24 2010 87 96
48. E. Dejesus, B. Young, J.O. Morales-Ramirez, L. Sloan, D.J. Ward, and J.F. Flaherty Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients J Acquir Immune Defic Syndr 51 2009 163 174
49. Bangsberg DR, Ragland K, Monk A, Deeks S. A one-pill, once daily fixed dose combination (FDC) of efavirenz, emtricitabine, and tenofovir disoproxil fumarate (EFV/FTC/TDF) regimen is associated with higher unannounced pill count adherence than non-one pill, once-daily therapy. 17TH Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA. February 1619, 2010. Abstract 510.
50. B. Guyer, M. Miller, J. Ho, M. Haddad, E. Coakley, and D. McColl Trends in HIV-1 Resistance Mutations and Antiretroviral Prescription Data from 20032008 Journal of Managed Care Pharmacy 16 2010 165
51. F.S. Rousseau, J.O. Kahn, M. Thompson, D. Mildvan, D. Shepp, and J.P. Sommadossi Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil) J Antimicrob Chemother 48 2001 507 513
52. R.F. Schinazi Assessment of the relative potency of emtricitabine and lamivudine J Acquir Immune Defic Syndr 34 2003 243 245
53. K.A. Modrzejewski, and R.A. Herman Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor Ann Pharmacother 38 2004 1006 1014
54. J.Y. Feng, and K.S. Anderson Mechanistic studies comparing the incorporation of () and (-) isomers of 3TCTP by HIV-1 reverse transcriptase Biochemistry 38 1999 55 63
55. R.F. Schinazi, R.M. Lloyd Jr, M.H. Nguyen, D.L. Cannon, A. McMillan, and N. Ilksoy Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides Antimicrob Agents Chemother 37 1993 875 881
56. R. Hazen, and E.R. Lanier Assessment of the Relative Potency of Emtricitabine and Lamivudine J Acquir Immune Defic Syndr 34 2003 245 246
57. L.L. Ross, N. Parkin, P. Gerondelis, C. Chappey, M.R. Underwood, and M.H. St Clair Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility J Acquir Immune Defic Syndr 43 2006 567 570
58. R. Maserati, S.A. De, A. Uglietti, G. Colao, B.A. Di, and B. Bruzzone Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine AIDS 24 2010 1013 1018
59. C.A. Benson, H.C. van der, A. Lamarca, D.W. Haas, C.K. McDonald, and C.R. Steinhart A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV AIDS 18 2004 2269 2276
60. B.G. Gazzard, J. Anderson, A. Babiker, M. Boffito, G. Brook, and G. Brough British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 HIV Med 9 2008 563 608